Drug intelligence / Profile preview

gsk-580416

Development stage: Phase 1
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

GSK-580416 is an investigational antibacterial agent that was developed by GlaxoSmithKline (now GSK) as an oral small molecule for the treatment of bacterial infections, including respiratory tract infections. Its mechanism of action involves inhibition of bacterial type II DNA topoisomerase and ribosomal proteins, disrupting essential processes in bacterial replication and protein synthesis. The drug reached Phase 1 clinical trials but development was discontinued and it is not approved or marketed for any indication[1][4][5].

Targets

TOP2A (DNA topoisomerase II)Ribosomal protein (Ribosomal protein family)

Beyond the preview

Go deeper on gsk-580416.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gsk-580416.

Explore the full profile